Agenus Inc.
NASDAQ:AGENBiotechnology
-$0.01 today
- Market cap
- $289.58M
- Beta
- 1.54
- P/E (TTM)
- 1.7
- EPS (TTM)
- $1.70
Volume 0.88M
Average 0.82M
AGEN Gross Profit
Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.
Agenus Inc.NASDAQ: AGEN
Gross Profit · Q1 FY2026 · quarter ended Mar 2026
Gross profit growth accelerates
Q1 FY2026 gross profit of $33.15M rose 1277.4% year over year, ahead of the +289.3% change in trailing-twelve-month gross profit. Sequentially, it rose 24.2% from the prior quarter.
Context
- Gross profit amounted to 29.6% of revenue in FY2025, down 21.2 pp from a year earlier.
- Gross profit increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +1277.4% holds above the trailing-twelve-month pace of +289.3%.
Sources:Income StatementText generated from reported figures; not investment advice.
Gross Profit history
USD · from the income statement
- Latest · FY2025
- 33.84M USD
- Year-over-year change
- +164.4%
- 4-year CAGR
- -26.1%
| Period | Period end | Gross Profit | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 33.84M | +164.4% |
| FY2024 | 2024-12-31 | (52.55M) | +35.4% |
| FY2023 | 2023-12-31 | (81.37M) | +18.0% |
| FY2022 | 2022-12-31 | (99.24M) | -187.4% |
| FY2021 | 2021-12-31 | 113.59M | — |
Gross Profit vs competitors
How AGEN compares with its peers on the latest reported figures
- AGEN's LTM Mar 2026 gross profit of $64.58M is the highest of the 10 companies compared; the peer median is -$46K.
- Its year-over-year change of +289.3% is the highest of 9, against a peer median of -1.6%.
- Gross profit amounts to 52.1% of revenue for AGEN, versus a peer median of 49.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $64.58M | +289.3% | — | 52.1% | |
| LTM Mar 2026 | $7.26M | +61.1% | +70.5% | 48.3% | |
IRDOpus Genetics, Inc. | LTM Mar 2026 | $5.95M | +1.3% | -29.1% | 49.6% |
| LTM Mar 2026 | -$23.47K | +63.1% | — | — | |
TTRXTurn Therapeutics Inc. | LTM Mar 2026 | -$42.29K | — | — | — |
| LTM Mar 2026 | -$46K | -4.5% | — | — | |
| LTM Mar 2026 | -$151K | -100.6% | — | — | |
| LTM Mar 2026 | -$711K | -14.3% | — | — | |
| LTM Mar 2026 | -$2.24M | -69.6% | -81.5% | — | |
| LTM Mar 2026 | -$26.26M | +63.7% | — | 415.8% | |
| Peer median (excluding AGEN) | -$46K | -1.6% | -29.1% | 49.6% | |
Competitors are the stored peer set for AGEN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 295.67M | 98.02M | 156.31M | 103.46M | 114.2M |
| Cost of Revenue | 182.08M | 197.26M | 237.68M | 156.01M | 80.36M |
| Gross Profit | 113.59M | (99.24M) | (81.37M) | (52.55M) | 33.84M |
| Gross Margin | 38.4% | -101.2% | -52.1% | -50.8% | 29.6% |
| Research & Development | 178.61M | 0 | 234.57M | 155.53M | 0 |
| Selling, General & Admin | 76.36M | 81.01M | 78.74M | 71.88M | 54.39M |
| Operating Expenses | 87.84M | 80.19M | 78.18M | 67.92M | 54.39M |
| Depreciation & Amortization | 6.79M | 6.95M | 13.59M | 13.34M | 10M |
| EBITDA | 43.78M | (161.85M) | (145.92M) | (101.3M) | 62.19M |
| EBITDA Margin | 14.8% | -165.1% | -93.4% | -97.9% | 54.5% |
| Operating Income | 25.75M | (179.43M) | (159.55M) | (120.48M) | (20.56M) |
| Operating Margin | 8.7% | -183.0% | -102.1% | -116.4% | -18.0% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 65.72M | 61.86M | 97.93M | 117.63M | 55.27M |
| Other Income / Expenses | (54.47M) | (51.23M) | (97.89M) | (111.8M) | 17.47M |
| Income Before Tax | (28.72M) | (230.66M) | (257.44M) | (232.27M) | (3.08M) |
| Pre-Tax Margin | -9.7% | -235.3% | -164.7% | -224.5% | -2.7% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (23.93M) | (220.07M) | (245.76M) | (227.21M) | 115K |
| Net Margin | -8.1% | -224.5% | -157.2% | -219.6% | 0.1% |
| EPS (Basic) | (2.11) | (15.64) | (13.75) | (10.59) | (0.00) |
| EPS (Diluted) | (2.11) | (15.64) | (13.75) | (10.59) | (0.00) |
| Weighted Avg Shares | 11.45M | 14.09M | 17.89M | 21.47M | 29.73M |
| Weighted Avg Shares (Diluted) | 11.45M | 14.09M | 17.89M | 21.47M | 29.73M |
Agenus Inc.
NASDAQ:AGEN
Intrinsic Alpha fair value
Locked
Current Price
$6.40
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.